Cargando…
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
BACKGROUND & AIMS: Cirrhosis is associated with immune dysregulation and hyporesponsiveness to several vaccines including those against COVID-19. Our aim was to compare outcomes between patients with cirrhosis who received 3 doses of either the Pfizer BNT162b2 mRNA or Moderna mRNA-1273 vaccines...
Autores principales: | John, Binu V., Ferreira, Raphaella D., Doshi, Akash, Kaplan, David E., Taddei, Tamar H., Spector, Seth A., Paulus, Elizabeth, Deng, Yangyang, Bastaich, Dustin, Dahman, Bassam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519143/ https://www.ncbi.nlm.nih.gov/pubmed/36181987 http://dx.doi.org/10.1016/j.jhep.2022.07.036 |
Ejemplares similares
-
Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022) -
782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022) -
Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
por: John, Binu, et al.
Publicado: (2022) -
Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis
por: John, Binu V., et al.
Publicado: (2022) -
Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)